Patent ID: 7417062

Claim:
A compound having the formula: and all pharmaceutically acceptable salts thereof, wherein the subscript n is an integer of from 1 to 3; R 1 is a member selected from the group consisting of hydrogen, halogen, C 1-8 alkoxy, C 1-8 alkyl, C 1-8 haloalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkoxy, C 3-6 cycloalkyl C 1-4 alkyl and C 3-6 cycloalkyl C 1-4 alkoxy; R 2 and R 3 are each members independently selected from C 1-8 alkyl and C 1-8 haloalkyl, or are optionally combined with the oxygen atoms to which each is attached to form a five- to ten-membered ring optionally substituted with from one to four substituents selected from the group consisting of C 1-4 alkyl and C 1-4 haloalkyl; X is a member selected from the group consisting of a bond, CH 2 and —C(CH 3 )—; Ar is a substituted or unsubstituted fused bicyclic aromatic ring system selected from the group consisting of naphthyl, quinolinyl, benzothienyl, isoquinolinyl, benzofuranyl, indolyl, benzothiazolyl, benzimidazolyl, 1,4-benzodioxan, quinoxalinyl, quinazolinyl, cinnolinyl and naphthyridinyl, or is a substituted or unsubstituted linked aromatic ring system selected from the group consisting of biphenyl, phenylthiazolyl, phenylpyrazolyl, pyridylthiazolyl and phenyl substituted with a 5- or 6-membered heteroaryl moiety selected from the group consisting of thiazolyl, thienyl, imidazolyl, pyrazolyl, furyl, oxazolyl, pyridyl, pyrimidinyl and pyrazinyl; and Z is a pyrrolidine ring that is optionally substituted with from one to four R 4 substituents independently selected from the group consisting of C 1-8 alkyl, C 1-8 haloalkyl, C 3-6 cycloalkyl, C 2-8 alkenyl, C 2-8 alkynyl, —COR a , —CO 2 R a , —CONR a R b , NR a COR b , —SO 2 R a , —X 1 COR a , —X 1 CO 2 R a , —X 1 CONR a R b , —X 1 NR a COR b , —X 1 SO 2 R a , —X 1 SO 2 NR a R b , —X 1 NR a R b , —X 1 OR a and —X 1 R a , wherein X 1 is a member selected from the group consisting of C 1-4 alkylene and C 2-4 alkenylene and each R a and R b is independently selected from the group consisting of hydrogen, C 1-8 alkyl, C 1-8 haloalkyl, C 3-6 cycloalkyl, C 3-9 heterocyclo-alkyl and aryl-C 1-4 alkyl, and wherein the aliphatic portions of each of said R 4 substituents is optionally substituted with from one to three members selected from the group consisting of —OH, —OR m , —OC(O)NHR m , —OC(O)N(R m ) 2 , —SH, —SR m , —S(O)R m , —S(O) 2 R m , —SO 2 NH 2 , —S(O) 2 NHR m , —S(O) 2 N(R m ) 2 , —NHS(O) 2 R m , —NR m S(O) 2 R m , —C(O)NH 2 , —C(O)NHR m , —C(O)N(R m ) 2 , —C(O)R m , —NHC(O)R m , —NR m C(O)R m , —NHC(O)NH 2 , —NR m C(O)NH 2 , —NR m C(O)NHR m , —NHC(O)NHR m , —NR m C(O)N(R m ) 2 , —NHC(O)N(R m ) 2 , —CO 2 H, —CO 2 R m , —NHCO 2 R m , —NR m CO 2 R m , —CN, —NO 2 , —NH 2 , —NHR m , —N(R m ) 2 , —NR m S(O)NH 2 and —NR m S(O) 2 NHR m , wherein each R m is independently an unsubstituted C 1-6 alkyl; and optionally, two R 4 substituents on adjacent carbon atoms are combined to form a fused six-membered ring that is saturated.